Genetic and pharmacological inhibition of FGFR1 and PLK1 synergizes to enhance anti‐proliferative effects and drive apoptosis in KRAS‐mutant lung and pancreatic cancer cells. Here, FGFR1 is linked to pancreatic neoplasm.